AR078270A1 - Inhibidores de jak (quinasas janus) - Google Patents
Inhibidores de jak (quinasas janus)Info
- Publication number
- AR078270A1 AR078270A1 ARP100103284A ARP100103284A AR078270A1 AR 078270 A1 AR078270 A1 AR 078270A1 AR P100103284 A ARP100103284 A AR P100103284A AR P100103284 A ARP100103284 A AR P100103284A AR 078270 A1 AR078270 A1 AR 078270A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- cycloalkyl
- cyano
- halogen
- alkoxy
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 23
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 12
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Inhibidores de JAK. Que son utiles para el tratamiento de enfermedades inflamatorias y autoinmunes. Reivindicacion 1: Un compuesto de Formula 1 en el que: R es alquilo inferior, haloalquilo inferior, alcoxi inferior, hidroxi alquilo inferior, hidroxi, o halogeno; n es 0 o 1; Z1 es CH, NH, o S; Z2 es CH o N; Z3 es CR1, N, o NR2; R1 es H, alquilo inferior, cicloalquilo, ciano, ciano alquilo inferior, o halogeno; R2 es H o alquilo inferior; X es CH, CR', o N; X' es CH, CR', o N; r es 0 o 1; Y es CH, CR', o N; R' es R'a o Rb; R'a es halogeno o ciano; R'b es alquilo inferior, cicloalquilo, heterocicloalquilo, OR'', SR'', S(=O)2R'' o NR''R'', sustituido opcionalmente con uno o más R'c; R'c es hidroxi, halogeno, oxo, ciano, alquilo inferior, cicloalquilo, heterocicloalquilo, heteroarilo, carboxi alquilo inferior, amino-carbonil-alquilamino inferior, alquilamino inferior, dialquilamino inferior, haloalquilo inferior, o alcoxi inferior; m es 0 o 1; R'' es H, alquilo inferior, hidroxi alquilo inferior, heterocicloalquilo, cicloalquilo, heteroarilo, o alcoxi inferior; Q es H, S(=O)2Q1, C(=O)Q2, C(=O)OQ3, o Q4;Q1 es alquilo inferior, cicloalquil alquilo inferior, alquilamino inferior, dialquil amino inferior o cicloalquilo, sustituido opcionalmente con uno o más Q1'; cada Q1' es independientemente halogeno, alquilo inferior, ciano, o alcoxi inferior; Q2 es alquilo inferior, cicloalquil alquilo inferior, o cicloalquilo, sustituido opcionalmente con uno o más Q2'; cada Q2' es independientemente halogeno, alquilo inferior, ciano o alcoxi inferior; Q3 es alquilo inferior, cicloalquil alquilo inferior, o cicloalquilo, sustituido opcionalmente con uno o más Q3'; cada Q3' es independientemente halogeno, alquilo inferior, o alcoxi inferior; Q4 es alquilo inferior, cicloalquil alquilo inferior, heterocicloalquilo, o cicloalquilo, sustituido opcionalmente con uno o más Q4'; cada Q4' es independientemente halogeno, ciano, ciano alquilo inferior, alquilo inferior, o alcoxi inferior; p es 0, 1, o 2; q es 1 o 2; cada ------ representa un enlace sencillo o un doble enlace; y con la condicion que los enlaces entre Z1 y Z2 y Z2 y Z3 no son los dos enlaces dobles y no son los dos enlaces sencillos; o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24109509P | 2009-09-10 | 2009-09-10 | |
| US36763910P | 2010-07-26 | 2010-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078270A1 true AR078270A1 (es) | 2011-10-26 |
Family
ID=42990260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103284A AR078270A1 (es) | 2009-09-10 | 2010-09-08 | Inhibidores de jak (quinasas janus) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8618103B2 (es) |
| EP (1) | EP2475667A1 (es) |
| JP (1) | JP5658756B2 (es) |
| KR (1) | KR101481872B1 (es) |
| CN (1) | CN102596962A (es) |
| AR (1) | AR078270A1 (es) |
| BR (1) | BR112012005382A2 (es) |
| CA (1) | CA2773182A1 (es) |
| MX (1) | MX2012002641A (es) |
| RU (1) | RU2538204C2 (es) |
| TW (1) | TW201120041A (es) |
| WO (1) | WO2011029804A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2710006A1 (en) | 2011-05-17 | 2014-03-26 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| US9073947B2 (en) * | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| WO2014146493A1 (en) * | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors |
| MX383686B (es) | 2013-07-31 | 2025-03-14 | Novartis Ag | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. |
| DK3297992T3 (da) | 2015-05-22 | 2020-04-20 | Chong Kun Dang Pharmaceutical Corp | Heterocykliske alkylderivatforbindelser som selektive histondeacetylase-inhibitorer og farmaceutiske sammensætninger omfattende samme |
| KR102780243B1 (ko) | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| PE20201202A1 (es) | 2018-04-26 | 2020-11-11 | Pfizer | Inhibidores de cinasa dependientes de ciclina |
| CN108707150B (zh) * | 2018-05-14 | 2021-04-16 | 江苏惠利生物科技有限公司 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN108395436B (zh) * | 2018-05-14 | 2021-01-12 | 鹤壁市人民医院 | 一种咪唑并吡嗪医药中间体的制备方法 |
| BR112020025642A2 (pt) | 2018-08-13 | 2021-03-23 | F. Hoffmann-La Roche Ag | compostos heterocíclicos como inibidores da monoacilglicerol lipase |
| RS65912B1 (sr) | 2018-08-13 | 2024-10-31 | Hoffmann La Roche | Nova heterociklična jedinjenja kao inhibitori monoacilglicerol lipaze |
| AU2019350592B2 (en) * | 2018-09-29 | 2024-09-26 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of SHP2 |
| PL3883936T3 (pl) | 2018-11-22 | 2023-11-20 | F. Hoffmann-La Roche Ag | Nowe związki heterocykliczne |
| PL3915989T3 (pl) | 2019-01-30 | 2023-12-11 | Felicamed Biotechnology Co., Ltd | Inhibitor jak i sposób jego otrzymywania |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| ATE430149T1 (de) | 1998-03-04 | 2009-05-15 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
| WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| EP1377572A1 (en) * | 2001-04-10 | 2004-01-07 | Vertex Pharmaceuticals Incorporated | Isoxaxole derivatives as inhibitors of src and other protein kinases |
| WO2002092573A2 (en) * | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| US7592340B2 (en) | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| ZA200710379B (en) | 2005-05-20 | 2009-05-27 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
| BRPI0613876A2 (pt) * | 2005-07-29 | 2011-02-15 | Pfizer Prod Inc | derivados de pirrolo [2,3-d] pirimidina; seus intermediários e sìntese |
| SI3184526T1 (sl) * | 2005-12-13 | 2019-03-29 | Incyte Holdings Corporation | Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze |
| EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| CA2675288A1 (en) * | 2007-01-12 | 2008-07-17 | Astellas Pharma Inc. | Condensed pyridine compound |
| EP2183243A2 (en) * | 2007-08-01 | 2010-05-12 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| CN101939324B (zh) * | 2008-02-25 | 2014-10-15 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| CA2713324A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| UY31881A (es) | 2008-06-10 | 2010-01-29 | Abbott Lab | Derivados sustituidos de imidazo[1,5-a]pirrolo[2,3-e]pirazinas e imidazo[1,2-a]pirrolo[2,3-e]pirazinas, sus sales, prodrogas, metabolitos biológicalmente activos, estereoisómeros e isómeros farmacéuticamente aceptables. |
| WO2010063634A1 (en) * | 2008-12-05 | 2010-06-10 | F. Hoffmann-La Roche Ag | Pyrrolopyrazinyl urea kinase inhibitors |
-
2010
- 2010-09-07 CN CN2010800504624A patent/CN102596962A/zh active Pending
- 2010-09-07 WO PCT/EP2010/063073 patent/WO2011029804A1/en not_active Ceased
- 2010-09-07 BR BR112012005382A patent/BR112012005382A2/pt not_active IP Right Cessation
- 2010-09-07 JP JP2012528338A patent/JP5658756B2/ja not_active Expired - Fee Related
- 2010-09-07 KR KR1020127009125A patent/KR101481872B1/ko not_active Expired - Fee Related
- 2010-09-07 EP EP10760280A patent/EP2475667A1/en not_active Withdrawn
- 2010-09-07 CA CA2773182A patent/CA2773182A1/en not_active Abandoned
- 2010-09-07 RU RU2012113593/04A patent/RU2538204C2/ru not_active IP Right Cessation
- 2010-09-07 TW TW099130224A patent/TW201120041A/zh unknown
- 2010-09-07 MX MX2012002641A patent/MX2012002641A/es active IP Right Grant
- 2010-09-08 AR ARP100103284A patent/AR078270A1/es unknown
- 2010-09-09 US US12/878,048 patent/US8618103B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012113593A (ru) | 2013-10-20 |
| TW201120041A (en) | 2011-06-16 |
| MX2012002641A (es) | 2012-03-14 |
| US20110059118A1 (en) | 2011-03-10 |
| WO2011029804A1 (en) | 2011-03-17 |
| RU2538204C2 (ru) | 2015-01-10 |
| EP2475667A1 (en) | 2012-07-18 |
| JP2013504532A (ja) | 2013-02-07 |
| US8618103B2 (en) | 2013-12-31 |
| CA2773182A1 (en) | 2011-03-17 |
| BR112012005382A2 (pt) | 2016-03-29 |
| JP5658756B2 (ja) | 2015-01-28 |
| KR101481872B1 (ko) | 2015-01-12 |
| CN102596962A (zh) | 2012-07-18 |
| KR20120135398A (ko) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078270A1 (es) | Inhibidores de jak (quinasas janus) | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| CO6480927A2 (es) | Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
| PH12014500883A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| AR065280A1 (es) | Agentes antiparasitarios | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
| EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
| AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
| CO6361936A2 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
| CR11819A (es) | Compuestos de isoindolina 5-sustituidos | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| EA201290632A1 (ru) | Производные бетулина | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| CO6680665A2 (es) | Derivados de 5-yodo-triazol | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| EA201190293A1 (ru) | Пролекарства триптолида | |
| CU20090064A7 (es) | Nuevos derivados de benzamida como antagonistas de la bradiquinina | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| EA200801199A1 (ru) | Ингибиторы киназы | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| EA201290229A1 (ru) | Производные спиролактама и их применение | |
| MA50093B1 (fr) | Composé pentacyclique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |